Total
0
Shares
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu
CEO and MD, Dr Oludare Odumosu
Source: Zelira Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelira Therapeutics (ZLD) signs a licensing deal for its Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology
  • DRCN Holding will pay a US$1 million (A$1.35 million) licensing fee for the tech and has three years to develop up to three products
  • The contract comes after the ASX-lister successfully demonstrated the enhanced dissolution of cannabinoids using EDCDM
  • Company shares are up 10.5 per cent at 4.2 cents each

Zelira Therapeutics (ZLD) has signed a licensing deal for its Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology.

The medicinal cannabis business will be paid a US$1 million (A$1.35 million) non-refundable, non-contingent licensing fee by DRCN Holding.

The milestone deal comes after the ASX-lister successfully demonstrated the enhanced dissolution of cannabinoids using its EDCDM technology.

Tech breakthrough

Zelira Therapeutics Global Managing Director & CEO Oludare Odumosu said its tech allows the cannabinoids to better dissolve upon consumption.

“Reflecting Zelira’s biopharmaceutical business strategy, we have solved two key issues holding back wider acceptance and usage of cannabinoid medicinal products – the difficulty in formulating solid oral dosage drugs with distillate, and the low rate of dissolution into the body from capsules and tablets,” he said.

“We have now demonstrated that Zelira’s proprietary EDCDM technology substantially traps the distillate in a free flow powder matrix and increases the rate of dissolution.

“This is a very exciting development as it opens multiple product development and commercialisation paths for medicinal cannabinoids.”

Foundation contract

Following the breakthrough, Zelira announced on Wednesday it would be teaming up with the US-based cannabis business.

DRCN will have at least three years to create three products using Zelira’s novel technology under the licensing contract recently signed.

In return, ZLD will receive 20 per cent of any revenue generated from the sales of the products created.

It’s also been promised the products will generate at least US$1 million (A$1.35 million) in net sales each year post commercialisation, or the contract can be cancelled.

“Receipt of the upfront, non-refundable, non-contingent fee under this transaction, will further strengthen Zelira’s cash position,” Mr Odumosu said.

“This puts the company in an increased strong position to continue to accelerate both
our prescription and Over The Counter businesses/strategies.”

Shares in Zelira Therapeutics were up 10.5 per cent at 4.2 cents each at 11:54 am AEDT.

ZLD by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug